Literature DB >> 19319841

Interferons and viral infections.

Volker Fensterl1, Ganes C Sen.   

Abstract

Interferons represent a family of cytokines, which is of central importance in the innate immune response to virus infections. All interferons act as secreted ligands of specific cell surface receptors, eliciting the transcription of hundreds of interferon-stimulated genes whose protein products have antiviral activity, as well as antimicrobial, antiproliferative/antitumor, and immunomodulatory effects. Expression of type I and III interferons is induced in virtually all cell types upon recognition of viral molecular patterns, especially nucleic acids, by cytoplasmic and endosomal receptors, whereas type II interferon is induced by cytokines such as IL-12, and its expression is restricted to immune cells such as T cells and NK cells. The effectiveness of the interferon system in counteracting viral infections is reflected by the multitude of inhibitors of interferon induction or interferon action that are encoded by many viruses, preventing their eradication and resulting in the continued coexistence of viruses and vertebrates. The unique biological functions of interferons have led to their therapeutic use in the treatment of diseases such as hepatitis, multiple sclerosis, and certain leukemias.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19319841     DOI: 10.1002/biof.6

Source DB:  PubMed          Journal:  Biofactors        ISSN: 0951-6433            Impact factor:   6.113


  155 in total

1.  The inhibitory action of P56 on select functions of E1 mediates interferon's effect on human papillomavirus DNA replication.

Authors:  Paramananda Saikia; Volker Fensterl; Ganes C Sen
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

Review 2.  Into the eye of the cytokine storm.

Authors:  Jennifer R Tisoncik; Marcus J Korth; Cameron P Simmons; Jeremy Farrar; Thomas R Martin; Michael G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2012-03       Impact factor: 11.056

Review 3.  Treatment of hepatitis C in 2011: what can we expect?

Authors:  Mitchell L Shiffman
Journal:  Curr Gastroenterol Rep       Date:  2010-02

4.  Identification of novel gene signatures in patients with atopic dermatitis complicated by eczema herpeticum.

Authors:  Lianghua Bin; Michael G Edwards; Ryan Heiser; Joanne E Streib; Brittany Richers; Clifton F Hall; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2014-08-23       Impact factor: 10.793

5.  Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.

Authors:  Anne Schaap-Nutt; Caraline Higgins; Emerito Amaro-Carambot; Sheila M Nolan; Christopher D'Angelo; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

6.  An ITAM in a nonenveloped virus regulates activation of NF-κB, induction of beta interferon, and viral spread.

Authors:  Rachael E Stebbing; Susan C Irvin; Efraín E Rivera-Serrano; Karl W Boehme; Mine Ikizler; Jeffrey A Yoder; Terence S Dermody; Barbara Sherry
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

7.  Viral degradasome hijacks mitochondria to suppress innate immunity.

Authors:  Ramansu Goswami; Tanmay Majumdar; Jayeeta Dhar; Saurabh Chattopadhyay; Sudip K Bandyopadhyay; Valentina Verbovetskaya; Ganes C Sen; Sailen Barik
Journal:  Cell Res       Date:  2013-07-23       Impact factor: 25.617

8.  Mitogen-activated protein kinase-mediated licensing of interferon regulatory factor 3/7 reinforces the cell response to virus.

Authors:  Sonja Schmid; David Sachs; Benjamin R tenOever
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

9.  Increased expression of IL-28RA mRNA in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.

Authors:  Yu-Yan Cheng; Yu-Jun Sheng; Yan Chang; Yan Lin; Zheng-Wei Zhu; Lei-Lei Wen; Chao Yang; Lu Liu; Lu-Lu Yang; Fu-Sheng Zhou; Xiao-Dong Zheng; Xian-Yong Yin; Sheng-Quan Zhang; Yong Cui; Sen Yang; Xue-Jun Zhang
Journal:  Clin Rheumatol       Date:  2015-04-25       Impact factor: 2.980

10.  Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts.

Authors:  Dominick Santoriello; Syed A Husain; Sacha A De Serres; Andrew S Bomback; Russell J Crew; Elena-Rodica Vasilescu; Geo Serban; Eric S Campenot; Krzysztof Kiryluk; Sumit Mohan; Gregory A Hawkins; Pamela J Hicks; David J Cohen; Jai Radhakrishnan; Michael B Stokes; Glen S Markowitz; Barry I Freedman; Vivette D D'Agati; Ibrahim Batal
Journal:  Kidney Int       Date:  2018-10-02       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.